Cargando…
EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
For most adolescent and young adult (AYA) cancers, age‐specific molecular features are poorly understood. EORTC‐SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383917/ https://www.ncbi.nlm.nih.gov/pubmed/31465545 http://dx.doi.org/10.1002/ijc.32651 |
_version_ | 1783563518954438656 |
---|---|
author | de Rojas, Teresa Kasper, Bernd Van der Graaf, Winette Pfister, Stefan M. Bielle, Franck Ribalta, Teresa Shenjere, Patrick Preusser, Matthias Fröhling, Stefan Golfinopoulos, Vassilis Morfouace, Marie McCabe, Martin G. |
author_facet | de Rojas, Teresa Kasper, Bernd Van der Graaf, Winette Pfister, Stefan M. Bielle, Franck Ribalta, Teresa Shenjere, Patrick Preusser, Matthias Fröhling, Stefan Golfinopoulos, Vassilis Morfouace, Marie McCabe, Martin G. |
author_sort | de Rojas, Teresa |
collection | PubMed |
description | For most adolescent and young adult (AYA) cancers, age‐specific molecular features are poorly understood. EORTC‐SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in February 2019 across Europe, will recruit 100 AYA patients (aged 12–29 years) with newly diagnosed or relapsed high‐grade gliomas and high‐grade bone and soft tissue sarcomas. The primary objective of the pilot is to determine feasibility and recruitment rates. Formalin‐fixed tumor tissue and whole blood from study participants will be prospectively collected with clinical data and stored centrally at the Integrated BioBank of Luxembourg. Whole exome sequencing of matched tumor and blood, and tumor RNA sequencing and DNA methylation profiling will be performed at the German Cancer Research Center, Heidelberg, Germany. Virtual central pathology review of scanned diagnostic slides will be undertaken by an international expert panel, and diagnostic material returned to the participating centers. A multidisciplinary molecular tumor board will release a clinically validated report to referring clinicians within 4–6 weeks after biopsy. SPECTA‐AYA constitutes a major opportunity to gain knowledge about the tumor biology of this unique age group. It incorporates notable innovative aspects: AYA specificity, pan‐European academic collaboration, centralized biobanking, comprehensive molecular profiling and virtual central pathology review, among others. SPECTA‐AYA will help untangle the tumor particularities of AYAs with cancer and aims to improve their access to novel drugs and personalized medicine. |
format | Online Article Text |
id | pubmed-7383917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73839172020-07-27 EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe de Rojas, Teresa Kasper, Bernd Van der Graaf, Winette Pfister, Stefan M. Bielle, Franck Ribalta, Teresa Shenjere, Patrick Preusser, Matthias Fröhling, Stefan Golfinopoulos, Vassilis Morfouace, Marie McCabe, Martin G. Int J Cancer Molecular Cancer Biology For most adolescent and young adult (AYA) cancers, age‐specific molecular features are poorly understood. EORTC‐SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in February 2019 across Europe, will recruit 100 AYA patients (aged 12–29 years) with newly diagnosed or relapsed high‐grade gliomas and high‐grade bone and soft tissue sarcomas. The primary objective of the pilot is to determine feasibility and recruitment rates. Formalin‐fixed tumor tissue and whole blood from study participants will be prospectively collected with clinical data and stored centrally at the Integrated BioBank of Luxembourg. Whole exome sequencing of matched tumor and blood, and tumor RNA sequencing and DNA methylation profiling will be performed at the German Cancer Research Center, Heidelberg, Germany. Virtual central pathology review of scanned diagnostic slides will be undertaken by an international expert panel, and diagnostic material returned to the participating centers. A multidisciplinary molecular tumor board will release a clinically validated report to referring clinicians within 4–6 weeks after biopsy. SPECTA‐AYA constitutes a major opportunity to gain knowledge about the tumor biology of this unique age group. It incorporates notable innovative aspects: AYA specificity, pan‐European academic collaboration, centralized biobanking, comprehensive molecular profiling and virtual central pathology review, among others. SPECTA‐AYA will help untangle the tumor particularities of AYAs with cancer and aims to improve their access to novel drugs and personalized medicine. John Wiley & Sons, Inc. 2019-09-14 2020-08-15 /pmc/articles/PMC7383917/ /pubmed/31465545 http://dx.doi.org/10.1002/ijc.32651 Text en © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Molecular Cancer Biology de Rojas, Teresa Kasper, Bernd Van der Graaf, Winette Pfister, Stefan M. Bielle, Franck Ribalta, Teresa Shenjere, Patrick Preusser, Matthias Fröhling, Stefan Golfinopoulos, Vassilis Morfouace, Marie McCabe, Martin G. EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe |
title | EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe |
title_full | EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe |
title_fullStr | EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe |
title_full_unstemmed | EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe |
title_short | EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe |
title_sort | eortc specta‐aya: a unique molecular profiling platform for adolescents and young adults with cancer in europe |
topic | Molecular Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383917/ https://www.ncbi.nlm.nih.gov/pubmed/31465545 http://dx.doi.org/10.1002/ijc.32651 |
work_keys_str_mv | AT derojasteresa eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT kasperbernd eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT vandergraafwinette eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT pfisterstefanm eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT biellefranck eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT ribaltateresa eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT shenjerepatrick eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT preussermatthias eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT frohlingstefan eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT golfinopoulosvassilis eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT morfouacemarie eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope AT mccabemarting eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope |